SEC Form 4 · accession 0001562180-18-002587
Sienna Biopharmaceuticals, Inc. · SNNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
III Frederick Beddingfield
Officer — President & CEO · Director
Period of report
May 17, 2018
Accepted (ET)
May 21, 2018 · 9:05 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 17, 2018 | J | 47,594 | — | A | 601,246 | D | |
| Common StockF2 | holding | — | — | — | 14,076 | I | See Footnote | |
| Common StockF3 | holding | — | — | — | 14,076 | I | See Footnote | |
| Common StockF4 | holding | — | — | — | 112,614 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Dr. Beddingfield acquired the shares pursuant to a mandatory distribution from Venvest Biotech, LLC ("Venvest") for which Dr. Beddingfield has a previously disclosed economic interest in any gain associated with the shares of the Issuer's capital stock purchased by Venvest in the Issuer's Series A-3 and Series B Preferred Stock financings. Dr. Beddingfield has no management or voting rights in respect of Venvest (Including no voting or investment power with respect to shares of the Issuer's capital stock held by Venvest).
- F2The shares are directly held by Beddingfield Children's Trust fbo Catherine Sara Beddingfield.
- F3The shares are directly held by Beddingfield Children's Trust fbo Claire Elizabeth Beddingfield.
- F4The shares are directly held by the Beddingfield Family Trust.